nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—EGFR—brain cancer	0.331	1	CbGaD
Erlotinib—CYP1B1—Procarbazine—brain cancer	0.18	0.463	CbGbCtD
Erlotinib—UGT1A1—Etoposide—brain cancer	0.0319	0.0822	CbGbCtD
Erlotinib—CYP2D6—Lomustine—brain cancer	0.0247	0.0635	CbGbCtD
Erlotinib—CYP1A2—Carmustine—brain cancer	0.0244	0.0629	CbGbCtD
Erlotinib—ABCG2—Carboplatin—brain cancer	0.0209	0.0538	CbGbCtD
Erlotinib—CYP2D6—Hydroxyurea—brain cancer	0.0187	0.0481	CbGbCtD
Erlotinib—CYP3A4—Temozolomide—brain cancer	0.0185	0.0475	CbGbCtD
Erlotinib—ABCG2—Etoposide—brain cancer	0.0176	0.0452	CbGbCtD
Erlotinib—CYP3A4—Lomustine—brain cancer	0.0157	0.0404	CbGbCtD
Erlotinib—CYP3A5—Etoposide—brain cancer	0.00974	0.025	CbGbCtD
Erlotinib—CYP2C8—Etoposide—brain cancer	0.00936	0.0241	CbGbCtD
Erlotinib—CYP1A2—Etoposide—brain cancer	0.00725	0.0186	CbGbCtD
Erlotinib—ABCB1—Etoposide—brain cancer	0.00634	0.0163	CbGbCtD
Erlotinib—CYP3A4—Etoposide—brain cancer	0.0038	0.00976	CbGbCtD
Erlotinib—ULK3—ganglion—brain cancer	0.00181	0.0274	CbGeAlD
Erlotinib—HIPK4—gonad—brain cancer	0.00108	0.0164	CbGeAlD
Erlotinib—Vandetanib—VEGFA—brain cancer	0.00108	0.296	CrCbGaD
Erlotinib—SLCO2B1—ganglion—brain cancer	0.000974	0.0148	CbGeAlD
Erlotinib—MAP2K5—hindbrain—brain cancer	0.00095	0.0144	CbGeAlD
Erlotinib—AURKC—gonad—brain cancer	0.000924	0.014	CbGeAlD
Erlotinib—Vandetanib—EGFR—brain cancer	0.000908	0.25	CrCbGaD
Erlotinib—Gefitinib—EGFR—brain cancer	0.000863	0.237	CrCbGaD
Erlotinib—EPHA6—gonad—brain cancer	0.000856	0.013	CbGeAlD
Erlotinib—HIPK4—endocrine gland—brain cancer	0.000818	0.0124	CbGeAlD
Erlotinib—NR1I2—endocrine gland—brain cancer	0.000809	0.0123	CbGeAlD
Erlotinib—LTK—head—brain cancer	0.000799	0.0121	CbGeAlD
Erlotinib—NR1I2—head—brain cancer	0.000799	0.0121	CbGeAlD
Erlotinib—Gefitinib—CYP2C9—brain cancer	0.000787	0.216	CrCbGaD
Erlotinib—TNK1—pituitary gland—brain cancer	0.000767	0.0116	CbGeAlD
Erlotinib—EGFR—telencephalon—brain cancer	0.000754	0.0114	CbGeAlD
Erlotinib—ABL1—hindbrain—brain cancer	0.000733	0.0111	CbGeAlD
Erlotinib—PIP4K2C—telencephalon—brain cancer	0.000731	0.0111	CbGeAlD
Erlotinib—AURKC—endocrine gland—brain cancer	0.000699	0.0106	CbGeAlD
Erlotinib—ULK3—telencephalon—brain cancer	0.000698	0.0106	CbGeAlD
Erlotinib—AURKC—head—brain cancer	0.00069	0.0105	CbGeAlD
Erlotinib—FLT3—gonad—brain cancer	0.000675	0.0102	CbGeAlD
Erlotinib—MKNK1—telencephalon—brain cancer	0.000657	0.00996	CbGeAlD
Erlotinib—EPHA6—endocrine gland—brain cancer	0.000647	0.00981	CbGeAlD
Erlotinib—JAK3—endocrine gland—brain cancer	0.000647	0.00981	CbGeAlD
Erlotinib—EPHA6—head—brain cancer	0.000639	0.00969	CbGeAlD
Erlotinib—JAK3—head—brain cancer	0.000639	0.00969	CbGeAlD
Erlotinib—AURKC—central nervous system—brain cancer	0.000629	0.00955	CbGeAlD
Erlotinib—ABL2—pituitary gland—brain cancer	0.000629	0.00954	CbGeAlD
Erlotinib—SLK—telencephalon—brain cancer	0.000622	0.00943	CbGeAlD
Erlotinib—PIP4K2C—gonad—brain cancer	0.00061	0.00925	CbGeAlD
Erlotinib—PIP4K2C—pituitary gland—brain cancer	0.000595	0.00902	CbGeAlD
Erlotinib—TNK1—endocrine gland—brain cancer	0.000594	0.00901	CbGeAlD
Erlotinib—HIPK4—brain—brain cancer	0.000585	0.00888	CbGeAlD
Erlotinib—JAK3—central nervous system—brain cancer	0.000583	0.00884	CbGeAlD
Erlotinib—EPHA6—central nervous system—brain cancer	0.000583	0.00884	CbGeAlD
Erlotinib—ULK3—gonad—brain cancer	0.000582	0.00883	CbGeAlD
Erlotinib—MAP3K19—head—brain cancer	0.00058	0.0088	CbGeAlD
Erlotinib—LTK—brain—brain cancer	0.000579	0.00878	CbGeAlD
Erlotinib—PIP4K2C—medulla oblongata—brain cancer	0.000574	0.00871	CbGeAlD
Erlotinib—JAK3—cerebellum—brain cancer	0.00057	0.00864	CbGeAlD
Erlotinib—ULK3—pituitary gland—brain cancer	0.000568	0.00862	CbGeAlD
Erlotinib—ULK3—medulla oblongata—brain cancer	0.000548	0.00832	CbGeAlD
Erlotinib—MKNK1—gonad—brain cancer	0.000548	0.00831	CbGeAlD
Erlotinib—MAP2K5—brainstem—brain cancer	0.000544	0.00825	CbGeAlD
Erlotinib—MKNK1—pituitary gland—brain cancer	0.000535	0.00811	CbGeAlD
Erlotinib—MAP3K19—central nervous system—brain cancer	0.00053	0.00804	CbGeAlD
Erlotinib—PIP4K2C—midbrain—brain cancer	0.000525	0.00796	CbGeAlD
Erlotinib—TNK1—cerebellum—brain cancer	0.000523	0.00793	CbGeAlD
Erlotinib—MKNK1—medulla oblongata—brain cancer	0.000516	0.00783	CbGeAlD
Erlotinib—PIP4K2C—spinal cord—brain cancer	0.000512	0.00777	CbGeAlD
Erlotinib—FLT3—endocrine gland—brain cancer	0.00051	0.00774	CbGeAlD
Erlotinib—SLK—pituitary gland—brain cancer	0.000506	0.00768	CbGeAlD
Erlotinib—ULK3—midbrain—brain cancer	0.000501	0.0076	CbGeAlD
Erlotinib—AURKC—brain—brain cancer	0.0005	0.00758	CbGeAlD
Erlotinib—ULK3—spinal cord—brain cancer	0.000489	0.00741	CbGeAlD
Erlotinib—SLK—medulla oblongata—brain cancer	0.000489	0.00741	CbGeAlD
Erlotinib—MAP2K5—telencephalon—brain cancer	0.000483	0.00732	CbGeAlD
Erlotinib—MKNK1—midbrain—brain cancer	0.000472	0.00715	CbGeAlD
Erlotinib—Dermatitis bullous—Hydroxyurea—brain cancer	0.000466	0.00384	CcSEcCtD
Erlotinib—Neuropathy—Carmustine—brain cancer	0.000466	0.00384	CcSEcCtD
Erlotinib—JAK3—brain—brain cancer	0.000463	0.00702	CbGeAlD
Erlotinib—EPHA6—brain—brain cancer	0.000463	0.00702	CbGeAlD
Erlotinib—PIP4K2C—endocrine gland—brain cancer	0.000461	0.00699	CbGeAlD
Erlotinib—MKNK1—spinal cord—brain cancer	0.00046	0.00698	CbGeAlD
Erlotinib—Skin exfoliation—Temozolomide—brain cancer	0.000458	0.00377	CcSEcCtD
Erlotinib—PIP4K2C—head—brain cancer	0.000455	0.0069	CbGeAlD
Erlotinib—STK10—gonad—brain cancer	0.000451	0.00685	CbGeAlD
Erlotinib—Neuropathy—Temozolomide—brain cancer	0.00045	0.00371	CcSEcCtD
Erlotinib—FLT3—cerebellum—brain cancer	0.000449	0.00682	CbGeAlD
Erlotinib—SLK—midbrain—brain cancer	0.000447	0.00677	CbGeAlD
Erlotinib—Pneumonia—Procarbazine—brain cancer	0.000446	0.00368	CcSEcCtD
Erlotinib—Dry eye—Temozolomide—brain cancer	0.000443	0.00365	CcSEcCtD
Erlotinib—Infection—Lomustine—brain cancer	0.000443	0.00365	CcSEcCtD
Erlotinib—ULK3—endocrine gland—brain cancer	0.00044	0.00668	CbGeAlD
Erlotinib—Cardiovascular disorder—Etoposide—brain cancer	0.000437	0.0036	CcSEcCtD
Erlotinib—Thrombocytopenia—Lomustine—brain cancer	0.000436	0.00359	CcSEcCtD
Erlotinib—SLK—spinal cord—brain cancer	0.000436	0.00661	CbGeAlD
Erlotinib—Pain—Carboplatin—brain cancer	0.000436	0.00359	CcSEcCtD
Erlotinib—Neuropathy peripheral—Procarbazine—brain cancer	0.000435	0.00358	CcSEcCtD
Erlotinib—ULK3—head—brain cancer	0.000435	0.00659	CbGeAlD
Erlotinib—Stomatitis—Procarbazine—brain cancer	0.000432	0.00356	CcSEcCtD
Erlotinib—Sepsis—Carmustine—brain cancer	0.000431	0.00355	CcSEcCtD
Erlotinib—ABL2—cerebellum—brain cancer	0.000429	0.00651	CbGeAlD
Erlotinib—TNK1—brain—brain cancer	0.000425	0.00644	CbGeAlD
Erlotinib—Anorexia—Lomustine—brain cancer	0.000425	0.0035	CcSEcCtD
Erlotinib—Cellulitis—Etoposide—brain cancer	0.000422	0.00348	CcSEcCtD
Erlotinib—MAP3K19—brain—brain cancer	0.000421	0.00638	CbGeAlD
Erlotinib—ABL1—brainstem—brain cancer	0.00042	0.00637	CbGeAlD
Erlotinib—EGFR—cerebellum—brain cancer	0.000419	0.00635	CbGeAlD
Erlotinib—Epistaxis—Procarbazine—brain cancer	0.000418	0.00345	CcSEcCtD
Erlotinib—PIP4K2C—central nervous system—brain cancer	0.000415	0.0063	CbGeAlD
Erlotinib—MKNK1—endocrine gland—brain cancer	0.000414	0.00628	CbGeAlD
Erlotinib—MKNK1—head—brain cancer	0.000409	0.0062	CbGeAlD
Erlotinib—PIP4K2C—cerebellum—brain cancer	0.000406	0.00616	CbGeAlD
Erlotinib—Body temperature increased—Carboplatin—brain cancer	0.000403	0.00332	CcSEcCtD
Erlotinib—Haemoglobin—Procarbazine—brain cancer	0.0004	0.0033	CcSEcCtD
Erlotinib—Haemorrhage—Procarbazine—brain cancer	0.000398	0.00328	CcSEcCtD
Erlotinib—ULK3—central nervous system—brain cancer	0.000397	0.00602	CbGeAlD
Erlotinib—Inflammation—Etoposide—brain cancer	0.000396	0.00326	CcSEcCtD
Erlotinib—MAP2K5—pituitary gland—brain cancer	0.000393	0.00596	CbGeAlD
Erlotinib—ULK3—cerebellum—brain cancer	0.000388	0.00588	CbGeAlD
Erlotinib—Decreased appetite—Lomustine—brain cancer	0.000387	0.00319	CcSEcCtD
Erlotinib—Hepatic failure—Temozolomide—brain cancer	0.000387	0.00319	CcSEcCtD
Erlotinib—MAP2K5—medulla oblongata—brain cancer	0.000379	0.00576	CbGeAlD
Erlotinib—Pancreatitis—Hydroxyurea—brain cancer	0.000378	0.00311	CcSEcCtD
Erlotinib—SLCO2B1—telencephalon—brain cancer	0.000376	0.0057	CbGeAlD
Erlotinib—MKNK1—central nervous system—brain cancer	0.000373	0.00566	CbGeAlD
Erlotinib—ABL1—telencephalon—brain cancer	0.000373	0.00565	CbGeAlD
Erlotinib—Skin exfoliation—Etoposide—brain cancer	0.000366	0.00302	CcSEcCtD
Erlotinib—MKNK1—cerebellum—brain cancer	0.000365	0.00553	CbGeAlD
Erlotinib—Neuropathy—Etoposide—brain cancer	0.00036	0.00297	CcSEcCtD
Erlotinib—Gastrointestinal haemorrhage—Carmustine—brain cancer	0.00036	0.00297	CcSEcCtD
Erlotinib—Neutropenia—Hydroxyurea—brain cancer	0.00036	0.00297	CcSEcCtD
Erlotinib—Chills—Procarbazine—brain cancer	0.000357	0.00294	CcSEcCtD
Erlotinib—Arrhythmia—Procarbazine—brain cancer	0.000356	0.00293	CcSEcCtD
Erlotinib—Body temperature increased—Lomustine—brain cancer	0.000352	0.0029	CcSEcCtD
Erlotinib—Alopecia—Procarbazine—brain cancer	0.000352	0.0029	CcSEcCtD
Erlotinib—ABL2—brain—brain cancer	0.000349	0.00529	CbGeAlD
Erlotinib—MAP2K5—midbrain—brain cancer	0.000347	0.00526	CbGeAlD
Erlotinib—SLK—cerebellum—brain cancer	0.000346	0.00524	CbGeAlD
Erlotinib—Infestation NOS—Hydroxyurea—brain cancer	0.000343	0.00283	CcSEcCtD
Erlotinib—Infestation—Hydroxyurea—brain cancer	0.000343	0.00283	CcSEcCtD
Erlotinib—STK10—endocrine gland—brain cancer	0.000341	0.00517	CbGeAlD
Erlotinib—EGFR—brain—brain cancer	0.00034	0.00516	CbGeAlD
Erlotinib—MAP2K5—spinal cord—brain cancer	0.000338	0.00513	CbGeAlD
Erlotinib—STK10—head—brain cancer	0.000337	0.00511	CbGeAlD
Erlotinib—Neuropathy peripheral—Hydroxyurea—brain cancer	0.000337	0.00277	CcSEcCtD
Erlotinib—Stomatitis—Hydroxyurea—brain cancer	0.000335	0.00276	CcSEcCtD
Erlotinib—Sepsis—Etoposide—brain cancer	0.000333	0.00274	CcSEcCtD
Erlotinib—PIP4K2C—brain—brain cancer	0.00033	0.005	CbGeAlD
Erlotinib—Hypokalaemia—Carmustine—brain cancer	0.000328	0.0027	CcSEcCtD
Erlotinib—Hepatobiliary disease—Hydroxyurea—brain cancer	0.000325	0.00267	CcSEcCtD
Erlotinib—Dehydration—Temozolomide—brain cancer	0.000324	0.00267	CcSEcCtD
Erlotinib—UGT1A1—endocrine gland—brain cancer	0.000322	0.00489	CbGeAlD
Erlotinib—Dry skin—Temozolomide—brain cancer	0.000319	0.00263	CcSEcCtD
Erlotinib—Hypokalaemia—Temozolomide—brain cancer	0.000317	0.00261	CcSEcCtD
Erlotinib—CYP2D6—hindbrain—brain cancer	0.000317	0.0048	CbGeAlD
Erlotinib—CYP1B1—telencephalon—brain cancer	0.000316	0.00479	CbGeAlD
Erlotinib—ULK3—brain—brain cancer	0.000315	0.00478	CbGeAlD
Erlotinib—Toxic epidermal necrolysis—Temozolomide—brain cancer	0.000313	0.00258	CcSEcCtD
Erlotinib—Dysphagia—Carmustine—brain cancer	0.000311	0.00256	CcSEcCtD
Erlotinib—ABL1—gonad—brain cancer	0.000311	0.00472	CbGeAlD
Erlotinib—Syncope—Procarbazine—brain cancer	0.000311	0.00256	CcSEcCtD
Erlotinib—Haemoglobin—Hydroxyurea—brain cancer	0.00031	0.00255	CcSEcCtD
Erlotinib—Haemorrhage—Hydroxyurea—brain cancer	0.000308	0.00254	CcSEcCtD
Erlotinib—STK10—central nervous system—brain cancer	0.000307	0.00466	CbGeAlD
Erlotinib—Alanine aminotransferase increased—Temozolomide—brain cancer	0.000307	0.00253	CcSEcCtD
Erlotinib—Loss of consciousness—Procarbazine—brain cancer	0.000305	0.00251	CcSEcCtD
Erlotinib—MAP2K5—endocrine gland—brain cancer	0.000305	0.00462	CbGeAlD
Erlotinib—ABL1—pituitary gland—brain cancer	0.000303	0.0046	CbGeAlD
Erlotinib—Cough—Procarbazine—brain cancer	0.000303	0.00249	CcSEcCtD
Erlotinib—Dysphagia—Temozolomide—brain cancer	0.000301	0.00248	CcSEcCtD
Erlotinib—MAP2K5—head—brain cancer	0.000301	0.00456	CbGeAlD
Erlotinib—STK10—cerebellum—brain cancer	0.0003	0.00456	CbGeAlD
Erlotinib—MKNK1—brain—brain cancer	0.000296	0.00449	CbGeAlD
Erlotinib—SLCO2B1—medulla oblongata—brain cancer	0.000295	0.00448	CbGeAlD
Erlotinib—Arthralgia—Procarbazine—brain cancer	0.000295	0.00243	CcSEcCtD
Erlotinib—Myalgia—Procarbazine—brain cancer	0.000295	0.00243	CcSEcCtD
Erlotinib—Anxiety—Procarbazine—brain cancer	0.000294	0.00242	CcSEcCtD
Erlotinib—ABL1—medulla oblongata—brain cancer	0.000293	0.00444	CbGeAlD
Erlotinib—Neutropenia—Carmustine—brain cancer	0.000291	0.0024	CcSEcCtD
Erlotinib—Vomiting—Lomustine—brain cancer	0.000283	0.00233	CcSEcCtD
Erlotinib—Oedema—Procarbazine—brain cancer	0.000283	0.00233	CcSEcCtD
Erlotinib—Neutropenia—Temozolomide—brain cancer	0.000281	0.00232	CcSEcCtD
Erlotinib—Infection—Procarbazine—brain cancer	0.000281	0.00232	CcSEcCtD
Erlotinib—SLK—brain—brain cancer	0.000281	0.00426	CbGeAlD
Erlotinib—Pneumonia—Carmustine—brain cancer	0.000279	0.0023	CcSEcCtD
Erlotinib—Shock—Procarbazine—brain cancer	0.000278	0.00229	CcSEcCtD
Erlotinib—Thrombocytopenia—Procarbazine—brain cancer	0.000277	0.00228	CcSEcCtD
Erlotinib—Depression—Carmustine—brain cancer	0.000277	0.00228	CcSEcCtD
Erlotinib—Chills—Hydroxyurea—brain cancer	0.000277	0.00228	CcSEcCtD
Erlotinib—ORM1—spinal cord—brain cancer	0.000275	0.00417	CbGeAlD
Erlotinib—MAP2K5—central nervous system—brain cancer	0.000275	0.00416	CbGeAlD
Erlotinib—Renal failure—Carmustine—brain cancer	0.000273	0.00225	CcSEcCtD
Erlotinib—Alopecia—Hydroxyurea—brain cancer	0.000272	0.00224	CcSEcCtD
Erlotinib—Weight decreased—Temozolomide—brain cancer	0.000272	0.00224	CcSEcCtD
Erlotinib—Neuropathy peripheral—Carmustine—brain cancer	0.000272	0.00224	CcSEcCtD
Erlotinib—Stomatitis—Carmustine—brain cancer	0.000271	0.00223	CcSEcCtD
Erlotinib—Pneumonia—Temozolomide—brain cancer	0.00027	0.00222	CcSEcCtD
Erlotinib—Anorexia—Procarbazine—brain cancer	0.00027	0.00222	CcSEcCtD
Erlotinib—Erythema—Hydroxyurea—brain cancer	0.000268	0.00221	CcSEcCtD
Erlotinib—MAP2K5—cerebellum—brain cancer	0.000268	0.00407	CbGeAlD
Erlotinib—Infestation—Temozolomide—brain cancer	0.000268	0.00221	CcSEcCtD
Erlotinib—Infestation NOS—Temozolomide—brain cancer	0.000268	0.00221	CcSEcCtD
Erlotinib—ABL1—midbrain—brain cancer	0.000268	0.00406	CbGeAlD
Erlotinib—Depression—Temozolomide—brain cancer	0.000267	0.0022	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Temozolomide—brain cancer	0.000266	0.00219	CcSEcCtD
Erlotinib—Nausea—Lomustine—brain cancer	0.000265	0.00218	CcSEcCtD
Erlotinib—CYP1B1—gonad—brain cancer	0.000263	0.00399	CbGeAlD
Erlotinib—SLCO2B1—spinal cord—brain cancer	0.000263	0.00399	CbGeAlD
Erlotinib—Neuropathy peripheral—Temozolomide—brain cancer	0.000263	0.00217	CcSEcCtD
Erlotinib—Stomatitis—Temozolomide—brain cancer	0.000261	0.00215	CcSEcCtD
Erlotinib—ABL1—spinal cord—brain cancer	0.000261	0.00396	CbGeAlD
Erlotinib—Musculoskeletal discomfort—Procarbazine—brain cancer	0.000258	0.00212	CcSEcCtD
Erlotinib—CYP1B1—pituitary gland—brain cancer	0.000257	0.0039	CbGeAlD
Erlotinib—Insomnia—Procarbazine—brain cancer	0.000256	0.00211	CcSEcCtD
Erlotinib—Hepatobiliary disease—Temozolomide—brain cancer	0.000254	0.00209	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Etoposide—brain cancer	0.000251	0.00207	CcSEcCtD
Erlotinib—Haemoglobin—Carmustine—brain cancer	0.00025	0.00206	CcSEcCtD
Erlotinib—Haemorrhage—Carmustine—brain cancer	0.000249	0.00205	CcSEcCtD
Erlotinib—ORM1—endocrine gland—brain cancer	0.000247	0.00375	CbGeAlD
Erlotinib—Decreased appetite—Procarbazine—brain cancer	0.000246	0.00203	CcSEcCtD
Erlotinib—Alanine aminotransferase increased—Etoposide—brain cancer	0.000246	0.00202	CcSEcCtD
Erlotinib—Connective tissue disorder—Carmustine—brain cancer	0.000245	0.00202	CcSEcCtD
Erlotinib—STK10—brain—brain cancer	0.000244	0.0037	CbGeAlD
Erlotinib—Fatigue—Procarbazine—brain cancer	0.000244	0.00201	CcSEcCtD
Erlotinib—Haemoglobin—Temozolomide—brain cancer	0.000242	0.00199	CcSEcCtD
Erlotinib—Constipation—Procarbazine—brain cancer	0.000242	0.00199	CcSEcCtD
Erlotinib—Pain—Procarbazine—brain cancer	0.000242	0.00199	CcSEcCtD
Erlotinib—Hepatitis—Temozolomide—brain cancer	0.000241	0.00198	CcSEcCtD
Erlotinib—Haemorrhage—Temozolomide—brain cancer	0.000241	0.00198	CcSEcCtD
Erlotinib—Dysphagia—Etoposide—brain cancer	0.000241	0.00198	CcSEcCtD
Erlotinib—ABCB1—blood vessel—brain cancer	0.000239	0.00362	CbGeAlD
Erlotinib—Urinary tract disorder—Temozolomide—brain cancer	0.000238	0.00196	CcSEcCtD
Erlotinib—SLCO2B1—endocrine gland—brain cancer	0.000237	0.0036	CbGeAlD
Erlotinib—Connective tissue disorder—Temozolomide—brain cancer	0.000237	0.00195	CcSEcCtD
Erlotinib—Urethral disorder—Temozolomide—brain cancer	0.000236	0.00194	CcSEcCtD
Erlotinib—ABL1—endocrine gland—brain cancer	0.000235	0.00356	CbGeAlD
Erlotinib—ABCG2—telencephalon—brain cancer	0.000235	0.00356	CbGeAlD
Erlotinib—SLCO2B1—head—brain cancer	0.000234	0.00355	CbGeAlD
Erlotinib—Eye disorder—Carmustine—brain cancer	0.000233	0.00192	CcSEcCtD
Erlotinib—ABL1—head—brain cancer	0.000232	0.00352	CbGeAlD
Erlotinib—Gastrointestinal pain—Procarbazine—brain cancer	0.000231	0.00191	CcSEcCtD
Erlotinib—Erythema multiforme—Temozolomide—brain cancer	0.000228	0.00188	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.000227	0.00187	CcSEcCtD
Erlotinib—Neutropenia—Etoposide—brain cancer	0.000225	0.00185	CcSEcCtD
Erlotinib—Eye disorder—Temozolomide—brain cancer	0.000225	0.00185	CcSEcCtD
Erlotinib—Body temperature increased—Procarbazine—brain cancer	0.000224	0.00184	CcSEcCtD
Erlotinib—Abdominal pain—Procarbazine—brain cancer	0.000224	0.00184	CcSEcCtD
Erlotinib—ORM1—central nervous system—brain cancer	0.000223	0.00338	CbGeAlD
Erlotinib—Arrhythmia—Carmustine—brain cancer	0.000223	0.00183	CcSEcCtD
Erlotinib—Alopecia—Carmustine—brain cancer	0.00022	0.00181	CcSEcCtD
Erlotinib—Oedema—Hydroxyurea—brain cancer	0.000219	0.0018	CcSEcCtD
Erlotinib—Mental disorder—Carmustine—brain cancer	0.000218	0.0018	CcSEcCtD
Erlotinib—MAP2K5—brain—brain cancer	0.000218	0.00331	CbGeAlD
Erlotinib—Infection—Hydroxyurea—brain cancer	0.000218	0.00179	CcSEcCtD
Erlotinib—Mediastinal disorder—Temozolomide—brain cancer	0.000217	0.00179	CcSEcCtD
Erlotinib—Malnutrition—Carmustine—brain cancer	0.000217	0.00179	CcSEcCtD
Erlotinib—Erythema—Carmustine—brain cancer	0.000217	0.00179	CcSEcCtD
Erlotinib—Chills—Temozolomide—brain cancer	0.000216	0.00178	CcSEcCtD
Erlotinib—Pneumonia—Etoposide—brain cancer	0.000216	0.00178	CcSEcCtD
Erlotinib—Nervous system disorder—Hydroxyurea—brain cancer	0.000215	0.00177	CcSEcCtD
Erlotinib—Infestation NOS—Etoposide—brain cancer	0.000215	0.00177	CcSEcCtD
Erlotinib—Infestation—Etoposide—brain cancer	0.000215	0.00177	CcSEcCtD
Erlotinib—Thrombocytopenia—Hydroxyurea—brain cancer	0.000214	0.00177	CcSEcCtD
Erlotinib—SLCO2B1—central nervous system—brain cancer	0.000214	0.00324	CbGeAlD
Erlotinib—Stevens-Johnson syndrome—Etoposide—brain cancer	0.000213	0.00175	CcSEcCtD
Erlotinib—Alopecia—Temozolomide—brain cancer	0.000213	0.00175	CcSEcCtD
Erlotinib—Skin disorder—Hydroxyurea—brain cancer	0.000213	0.00175	CcSEcCtD
Erlotinib—ABL1—central nervous system—brain cancer	0.000212	0.00321	CbGeAlD
Erlotinib—Acute coronary syndrome—Etoposide—brain cancer	0.000212	0.00174	CcSEcCtD
Erlotinib—Renal failure—Etoposide—brain cancer	0.000211	0.00174	CcSEcCtD
Erlotinib—Mental disorder—Temozolomide—brain cancer	0.000211	0.00174	CcSEcCtD
Erlotinib—Neuropathy peripheral—Etoposide—brain cancer	0.00021	0.00173	CcSEcCtD
Erlotinib—Myocardial infarction—Etoposide—brain cancer	0.00021	0.00173	CcSEcCtD
Erlotinib—Back pain—Carmustine—brain cancer	0.00021	0.00173	CcSEcCtD
Erlotinib—Malnutrition—Temozolomide—brain cancer	0.00021	0.00173	CcSEcCtD
Erlotinib—Erythema—Temozolomide—brain cancer	0.00021	0.00173	CcSEcCtD
Erlotinib—Stomatitis—Etoposide—brain cancer	0.000209	0.00172	CcSEcCtD
Erlotinib—SLCO2B1—cerebellum—brain cancer	0.000209	0.00317	CbGeAlD
Erlotinib—Anorexia—Hydroxyurea—brain cancer	0.000209	0.00172	CcSEcCtD
Erlotinib—ABL1—cerebellum—brain cancer	0.000207	0.00314	CbGeAlD
Erlotinib—Asthenia—Procarbazine—brain cancer	0.000203	0.00167	CcSEcCtD
Erlotinib—Hepatobiliary disease—Etoposide—brain cancer	0.000203	0.00167	CcSEcCtD
Erlotinib—Back pain—Temozolomide—brain cancer	0.000203	0.00167	CcSEcCtD
Erlotinib—Pruritus—Procarbazine—brain cancer	0.0002	0.00165	CcSEcCtD
Erlotinib—CYP1B1—endocrine gland—brain cancer	0.000199	0.00302	CbGeAlD
Erlotinib—CYP2C8—pituitary gland—brain cancer	0.000197	0.00298	CbGeAlD
Erlotinib—CYP1B1—head—brain cancer	0.000196	0.00298	CbGeAlD
Erlotinib—Dyspnoea—Hydroxyurea—brain cancer	0.000195	0.00161	CcSEcCtD
Erlotinib—Diarrhoea—Procarbazine—brain cancer	0.000194	0.00159	CcSEcCtD
Erlotinib—Dyspepsia—Hydroxyurea—brain cancer	0.000193	0.00159	CcSEcCtD
Erlotinib—ABCG2—pituitary gland—brain cancer	0.000191	0.0029	CbGeAlD
Erlotinib—Decreased appetite—Hydroxyurea—brain cancer	0.00019	0.00157	CcSEcCtD
Erlotinib—Urinary tract disorder—Etoposide—brain cancer	0.00019	0.00157	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.000189	0.00156	CcSEcCtD
Erlotinib—Urethral disorder—Etoposide—brain cancer	0.000189	0.00156	CcSEcCtD
Erlotinib—Fatigue—Hydroxyurea—brain cancer	0.000189	0.00156	CcSEcCtD
Erlotinib—Pain—Hydroxyurea—brain cancer	0.000187	0.00154	CcSEcCtD
Erlotinib—Constipation—Hydroxyurea—brain cancer	0.000187	0.00154	CcSEcCtD
Erlotinib—Dizziness—Procarbazine—brain cancer	0.000187	0.00154	CcSEcCtD
Erlotinib—Myalgia—Carmustine—brain cancer	0.000185	0.00152	CcSEcCtD
Erlotinib—Chest pain—Carmustine—brain cancer	0.000185	0.00152	CcSEcCtD
Erlotinib—ABCG2—medulla oblongata—brain cancer	0.000185	0.0028	CbGeAlD
Erlotinib—Anxiety—Carmustine—brain cancer	0.000184	0.00152	CcSEcCtD
Erlotinib—Cough—Temozolomide—brain cancer	0.000183	0.00151	CcSEcCtD
Erlotinib—Erythema multiforme—Etoposide—brain cancer	0.000182	0.0015	CcSEcCtD
Erlotinib—CYP2D6—brainstem—brain cancer	0.000181	0.00275	CbGeAlD
Erlotinib—Eye disorder—Etoposide—brain cancer	0.00018	0.00148	CcSEcCtD
Erlotinib—Vomiting—Procarbazine—brain cancer	0.00018	0.00148	CcSEcCtD
Erlotinib—CYP1B1—central nervous system—brain cancer	0.000179	0.00272	CbGeAlD
Erlotinib—Myalgia—Temozolomide—brain cancer	0.000178	0.00147	CcSEcCtD
Erlotinib—Arthralgia—Temozolomide—brain cancer	0.000178	0.00147	CcSEcCtD
Erlotinib—Rash—Procarbazine—brain cancer	0.000178	0.00147	CcSEcCtD
Erlotinib—Dermatitis—Procarbazine—brain cancer	0.000178	0.00147	CcSEcCtD
Erlotinib—Anxiety—Temozolomide—brain cancer	0.000178	0.00146	CcSEcCtD
Erlotinib—Headache—Procarbazine—brain cancer	0.000177	0.00146	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.000177	0.00146	CcSEcCtD
Erlotinib—Oedema—Carmustine—brain cancer	0.000177	0.00146	CcSEcCtD
Erlotinib—Infection—Carmustine—brain cancer	0.000176	0.00145	CcSEcCtD
Erlotinib—CYP1B1—cerebellum—brain cancer	0.000175	0.00266	CbGeAlD
Erlotinib—Mediastinal disorder—Etoposide—brain cancer	0.000174	0.00143	CcSEcCtD
Erlotinib—Thrombocytopenia—Carmustine—brain cancer	0.000173	0.00143	CcSEcCtD
Erlotinib—Body temperature increased—Hydroxyurea—brain cancer	0.000173	0.00143	CcSEcCtD
Erlotinib—Chills—Etoposide—brain cancer	0.000173	0.00142	CcSEcCtD
Erlotinib—Oedema—Temozolomide—brain cancer	0.000171	0.00141	CcSEcCtD
Erlotinib—Alopecia—Etoposide—brain cancer	0.00017	0.0014	CcSEcCtD
Erlotinib—Infection—Temozolomide—brain cancer	0.00017	0.0014	CcSEcCtD
Erlotinib—SLCO2B1—brain—brain cancer	0.00017	0.00257	CbGeAlD
Erlotinib—Anorexia—Carmustine—brain cancer	0.000169	0.00139	CcSEcCtD
Erlotinib—ABCG2—midbrain—brain cancer	0.000169	0.00256	CbGeAlD
Erlotinib—ABL1—brain—brain cancer	0.000168	0.00255	CbGeAlD
Erlotinib—Nausea—Procarbazine—brain cancer	0.000168	0.00138	CcSEcCtD
Erlotinib—Nervous system disorder—Temozolomide—brain cancer	0.000168	0.00138	CcSEcCtD
Erlotinib—Thrombocytopenia—Temozolomide—brain cancer	0.000168	0.00138	CcSEcCtD
Erlotinib—Skin disorder—Temozolomide—brain cancer	0.000166	0.00137	CcSEcCtD
Erlotinib—ABCG2—spinal cord—brain cancer	0.000165	0.0025	CbGeAlD
Erlotinib—Anorexia—Temozolomide—brain cancer	0.000163	0.00134	CcSEcCtD
Erlotinib—Back pain—Etoposide—brain cancer	0.000162	0.00134	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Carmustine—brain cancer	0.000161	0.00133	CcSEcCtD
Erlotinib—CYP2D6—telencephalon—brain cancer	0.000161	0.00244	CbGeAlD
Erlotinib—Insomnia—Carmustine—brain cancer	0.00016	0.00132	CcSEcCtD
Erlotinib—Dyspnoea—Carmustine—brain cancer	0.000158	0.0013	CcSEcCtD
Erlotinib—Asthenia—Hydroxyurea—brain cancer	0.000157	0.00129	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Temozolomide—brain cancer	0.000156	0.00128	CcSEcCtD
Erlotinib—ALB—brain—brain cancer	0.000155	0.00235	CbGeAlD
Erlotinib—Insomnia—Temozolomide—brain cancer	0.000155	0.00127	CcSEcCtD
Erlotinib—Decreased appetite—Carmustine—brain cancer	0.000154	0.00127	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Carmustine—brain cancer	0.000153	0.00126	CcSEcCtD
Erlotinib—Dyspnoea—Temozolomide—brain cancer	0.000153	0.00126	CcSEcCtD
Erlotinib—CYP2C8—endocrine gland—brain cancer	0.000152	0.00231	CbGeAlD
Erlotinib—Pain—Carmustine—brain cancer	0.000151	0.00125	CcSEcCtD
Erlotinib—Constipation—Carmustine—brain cancer	0.000151	0.00125	CcSEcCtD
Erlotinib—Dyspepsia—Temozolomide—brain cancer	0.000151	0.00124	CcSEcCtD
Erlotinib—Diarrhoea—Hydroxyurea—brain cancer	0.00015	0.00123	CcSEcCtD
Erlotinib—Decreased appetite—Temozolomide—brain cancer	0.000149	0.00122	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Temozolomide—brain cancer	0.000148	0.00122	CcSEcCtD
Erlotinib—Fatigue—Temozolomide—brain cancer	0.000148	0.00121	CcSEcCtD
Erlotinib—Loss of consciousness—Etoposide—brain cancer	0.000147	0.00121	CcSEcCtD
Erlotinib—Cough—Etoposide—brain cancer	0.000146	0.00121	CcSEcCtD
Erlotinib—Pain—Temozolomide—brain cancer	0.000146	0.00121	CcSEcCtD
Erlotinib—Constipation—Temozolomide—brain cancer	0.000146	0.00121	CcSEcCtD
Erlotinib—Dizziness—Hydroxyurea—brain cancer	0.000145	0.00119	CcSEcCtD
Erlotinib—Gastrointestinal pain—Carmustine—brain cancer	0.000145	0.00119	CcSEcCtD
Erlotinib—Chest pain—Etoposide—brain cancer	0.000143	0.00118	CcSEcCtD
Erlotinib—CYP1A2—endocrine gland—brain cancer	0.000143	0.00216	CbGeAlD
Erlotinib—CYP1B1—brain—brain cancer	0.000142	0.00216	CbGeAlD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.000142	0.00117	CcSEcCtD
Erlotinib—CYP1A1—endocrine gland—brain cancer	0.000141	0.00213	CbGeAlD
Erlotinib—Abdominal pain—Carmustine—brain cancer	0.00014	0.00115	CcSEcCtD
Erlotinib—Body temperature increased—Carmustine—brain cancer	0.00014	0.00115	CcSEcCtD
Erlotinib—Gastrointestinal pain—Temozolomide—brain cancer	0.00014	0.00115	CcSEcCtD
Erlotinib—Vomiting—Hydroxyurea—brain cancer	0.000139	0.00115	CcSEcCtD
Erlotinib—CYP1A1—head—brain cancer	0.000139	0.00211	CbGeAlD
Erlotinib—Rash—Hydroxyurea—brain cancer	0.000138	0.00114	CcSEcCtD
Erlotinib—Dermatitis—Hydroxyurea—brain cancer	0.000138	0.00114	CcSEcCtD
Erlotinib—CYP3A5—endocrine gland—brain cancer	0.000138	0.00209	CbGeAlD
Erlotinib—Headache—Hydroxyurea—brain cancer	0.000137	0.00113	CcSEcCtD
Erlotinib—Infection—Etoposide—brain cancer	0.000136	0.00112	CcSEcCtD
Erlotinib—Abdominal pain—Temozolomide—brain cancer	0.000135	0.00111	CcSEcCtD
Erlotinib—Body temperature increased—Temozolomide—brain cancer	0.000135	0.00111	CcSEcCtD
Erlotinib—Thrombocytopenia—Etoposide—brain cancer	0.000134	0.0011	CcSEcCtD
Erlotinib—Skin disorder—Etoposide—brain cancer	0.000133	0.0011	CcSEcCtD
Erlotinib—ABCG2—cerebellum—brain cancer	0.000131	0.00198	CbGeAlD
Erlotinib—Anorexia—Etoposide—brain cancer	0.000131	0.00107	CcSEcCtD
Erlotinib—Nausea—Hydroxyurea—brain cancer	0.00013	0.00107	CcSEcCtD
Erlotinib—Asthenia—Carmustine—brain cancer	0.000127	0.00105	CcSEcCtD
Erlotinib—CYP1A1—central nervous system—brain cancer	0.000127	0.00192	CbGeAlD
Erlotinib—Asthenia—Temozolomide—brain cancer	0.000123	0.00101	CcSEcCtD
Erlotinib—Dyspnoea—Etoposide—brain cancer	0.000122	0.00101	CcSEcCtD
Erlotinib—Diarrhoea—Carmustine—brain cancer	0.000121	0.000998	CcSEcCtD
Erlotinib—Pruritus—Temozolomide—brain cancer	0.000121	0.000997	CcSEcCtD
Erlotinib—Decreased appetite—Etoposide—brain cancer	0.000119	0.00098	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Etoposide—brain cancer	0.000118	0.000974	CcSEcCtD
Erlotinib—Fatigue—Etoposide—brain cancer	0.000118	0.000972	CcSEcCtD
Erlotinib—Dizziness—Carmustine—brain cancer	0.000117	0.000964	CcSEcCtD
Erlotinib—Pain—Etoposide—brain cancer	0.000117	0.000964	CcSEcCtD
Erlotinib—Constipation—Etoposide—brain cancer	0.000117	0.000964	CcSEcCtD
Erlotinib—Diarrhoea—Temozolomide—brain cancer	0.000117	0.000964	CcSEcCtD
Erlotinib—ABCB1—telencephalon—brain cancer	0.000116	0.00176	CbGeAlD
Erlotinib—Dizziness—Temozolomide—brain cancer	0.000113	0.000932	CcSEcCtD
Erlotinib—Vomiting—Carmustine—brain cancer	0.000113	0.000927	CcSEcCtD
Erlotinib—Gastrointestinal pain—Etoposide—brain cancer	0.000112	0.000922	CcSEcCtD
Erlotinib—Rash—Carmustine—brain cancer	0.000112	0.000919	CcSEcCtD
Erlotinib—Dermatitis—Carmustine—brain cancer	0.000112	0.000919	CcSEcCtD
Erlotinib—Headache—Carmustine—brain cancer	0.000111	0.000914	CcSEcCtD
Erlotinib—CYP2C8—brain—brain cancer	0.000109	0.00165	CbGeAlD
Erlotinib—Vomiting—Temozolomide—brain cancer	0.000109	0.000896	CcSEcCtD
Erlotinib—Abdominal pain—Etoposide—brain cancer	0.000108	0.000891	CcSEcCtD
Erlotinib—Body temperature increased—Etoposide—brain cancer	0.000108	0.000891	CcSEcCtD
Erlotinib—Rash—Temozolomide—brain cancer	0.000108	0.000888	CcSEcCtD
Erlotinib—Dermatitis—Temozolomide—brain cancer	0.000108	0.000888	CcSEcCtD
Erlotinib—Headache—Temozolomide—brain cancer	0.000107	0.000883	CcSEcCtD
Erlotinib—ABCG2—brain—brain cancer	0.000106	0.00161	CbGeAlD
Erlotinib—Nausea—Carmustine—brain cancer	0.000105	0.000866	CcSEcCtD
Erlotinib—CYP3A4—endocrine gland—brain cancer	0.000103	0.00157	CbGeAlD
Erlotinib—Nausea—Temozolomide—brain cancer	0.000102	0.000837	CcSEcCtD
Erlotinib—CYP2D6—endocrine gland—brain cancer	0.000102	0.00154	CbGeAlD
Erlotinib—CYP1A1—brain—brain cancer	0.000101	0.00153	CbGeAlD
Erlotinib—CYP2D6—head—brain cancer	0.0001	0.00152	CbGeAlD
Erlotinib—Asthenia—Etoposide—brain cancer	9.82e-05	0.000809	CcSEcCtD
Erlotinib—Pruritus—Etoposide—brain cancer	9.69e-05	0.000798	CcSEcCtD
Erlotinib—ABCB1—gonad—brain cancer	9.67e-05	0.00147	CbGeAlD
Erlotinib—ABCB1—pituitary gland—brain cancer	9.43e-05	0.00143	CbGeAlD
Erlotinib—Diarrhoea—Etoposide—brain cancer	9.37e-05	0.000772	CcSEcCtD
Erlotinib—CYP3A4—central nervous system—brain cancer	9.3e-05	0.00141	CbGeAlD
Erlotinib—CYP2D6—central nervous system—brain cancer	9.16e-05	0.00139	CbGeAlD
Erlotinib—ABCB1—medulla oblongata—brain cancer	9.1e-05	0.00138	CbGeAlD
Erlotinib—Dizziness—Etoposide—brain cancer	9.05e-05	0.000746	CcSEcCtD
Erlotinib—CYP2D6—cerebellum—brain cancer	8.95e-05	0.00136	CbGeAlD
Erlotinib—Vomiting—Etoposide—brain cancer	8.7e-05	0.000717	CcSEcCtD
Erlotinib—Rash—Etoposide—brain cancer	8.63e-05	0.000711	CcSEcCtD
Erlotinib—Dermatitis—Etoposide—brain cancer	8.62e-05	0.00071	CcSEcCtD
Erlotinib—Headache—Etoposide—brain cancer	8.58e-05	0.000706	CcSEcCtD
Erlotinib—ABCB1—midbrain—brain cancer	8.32e-05	0.00126	CbGeAlD
Erlotinib—Nausea—Etoposide—brain cancer	8.13e-05	0.00067	CcSEcCtD
Erlotinib—ABCB1—spinal cord—brain cancer	8.12e-05	0.00123	CbGeAlD
Erlotinib—ABCB1—endocrine gland—brain cancer	7.31e-05	0.00111	CbGeAlD
Erlotinib—CYP2D6—brain—brain cancer	7.27e-05	0.0011	CbGeAlD
Erlotinib—ABCB1—head—brain cancer	7.21e-05	0.00109	CbGeAlD
Erlotinib—ABCB1—central nervous system—brain cancer	6.59e-05	0.000999	CbGeAlD
Erlotinib—ABCB1—cerebellum—brain cancer	6.44e-05	0.000976	CbGeAlD
Erlotinib—ABCB1—brain—brain cancer	5.23e-05	0.000793	CbGeAlD
Erlotinib—EGFR—Disease—HEY1—brain cancer	1.73e-05	0.000194	CbGpPWpGaD
Erlotinib—EGFR—Direct p53 effectors—TP53—brain cancer	1.72e-05	0.000194	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—SHH—brain cancer	1.71e-05	0.000192	CbGpPWpGaD
Erlotinib—EGFR—Disease—DLL1—brain cancer	1.69e-05	0.000191	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—RELA—brain cancer	1.68e-05	0.000189	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—IDH1—brain cancer	1.68e-05	0.000189	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—ERBB2—brain cancer	1.67e-05	0.000188	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—VAV1—brain cancer	1.67e-05	0.000187	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—STAT3—brain cancer	1.66e-05	0.000187	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—BSG—brain cancer	1.66e-05	0.000186	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TRPC6—brain cancer	1.65e-05	0.000186	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—TRPC6—brain cancer	1.65e-05	0.000185	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	1.64e-05	0.000184	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—IRS2—brain cancer	1.63e-05	0.000183	CbGpPWpGaD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—TP53—brain cancer	1.62e-05	0.000183	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—SMO—brain cancer	1.62e-05	0.000182	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—PTCH1—brain cancer	1.62e-05	0.000182	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—PIK3CG—brain cancer	1.6e-05	0.00018	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—brain cancer	1.6e-05	0.00018	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—IRS2—brain cancer	1.59e-05	0.000179	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—PDGFRA—brain cancer	1.58e-05	0.000178	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	1.57e-05	0.000177	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—IDH1—brain cancer	1.57e-05	0.000176	CbGpPWpGaD
Erlotinib—MKNK1—Disease—ERBB2—brain cancer	1.56e-05	0.000175	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ABR—brain cancer	1.54e-05	0.000173	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—PIK3CG—brain cancer	1.53e-05	0.000172	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—PDGFRA—brain cancer	1.52e-05	0.000171	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—ERBB2—brain cancer	1.51e-05	0.00017	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—APC—brain cancer	1.5e-05	0.000169	CbGpPWpGaD
Erlotinib—EGFR—MAPK Signaling Pathway—TP53—brain cancer	1.49e-05	0.000168	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—GLI2—brain cancer	1.48e-05	0.000167	CbGpPWpGaD
Erlotinib—EGFR—Immune System—SKP2—brain cancer	1.48e-05	0.000166	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—CDK4—brain cancer	1.48e-05	0.000166	CbGpPWpGaD
Erlotinib—EGFR—Disease—ENO2—brain cancer	1.44e-05	0.000162	CbGpPWpGaD
Erlotinib—EGFR—Disease—SHH—brain cancer	1.44e-05	0.000162	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—HES1—brain cancer	1.43e-05	0.000161	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—TRPC6—brain cancer	1.43e-05	0.000161	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—IDH1—brain cancer	1.42e-05	0.00016	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—NOTCH2—brain cancer	1.42e-05	0.00016	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—TP53—brain cancer	1.41e-05	0.000159	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—APC—brain cancer	1.4e-05	0.000158	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—PIK3CG—brain cancer	1.4e-05	0.000158	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CYP2C9—brain cancer	1.4e-05	0.000157	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—GLI1—brain cancer	1.4e-05	0.000157	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—IRS2—brain cancer	1.39e-05	0.000157	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—IL2—brain cancer	1.39e-05	0.000156	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—IDH1—brain cancer	1.38e-05	0.000155	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—VEGFA—brain cancer	1.36e-05	0.000154	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—PDGFRA—brain cancer	1.36e-05	0.000154	CbGpPWpGaD
Erlotinib—MKNK1—Disease—CTNNB1—brain cancer	1.36e-05	0.000153	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—VAV1—brain cancer	1.36e-05	0.000153	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	1.34e-05	0.000151	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—IRS2—brain cancer	1.34e-05	0.00015	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—ENO2—brain cancer	1.33e-05	0.000149	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—SPP1—brain cancer	1.32e-05	0.000149	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SUFU—brain cancer	1.32e-05	0.000149	CbGpPWpGaD
Erlotinib—ABL1—Immune System—VAV1—brain cancer	1.32e-05	0.000148	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CYP2C9—brain cancer	1.32e-05	0.000148	CbGpPWpGaD
Erlotinib—JAK3—Immune System—RELA—brain cancer	1.28e-05	0.000144	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—GFAP—brain cancer	1.28e-05	0.000144	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—STAT3—brain cancer	1.28e-05	0.000144	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	1.27e-05	0.000143	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—RELA—brain cancer	1.27e-05	0.000143	CbGpPWpGaD
Erlotinib—JAK3—Immune System—ERBB2—brain cancer	1.27e-05	0.000143	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—ERBB2—brain cancer	1.26e-05	0.000142	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—IL2—brain cancer	1.26e-05	0.000142	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—TRPC6—brain cancer	1.25e-05	0.000141	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—VAV1—brain cancer	1.24e-05	0.000139	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—ENO2—brain cancer	1.24e-05	0.000139	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—VAV1—brain cancer	1.23e-05	0.000139	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—EGFR—brain cancer	1.23e-05	0.000138	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HEY1—brain cancer	1.21e-05	0.000136	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CYP2C9—brain cancer	1.21e-05	0.000136	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CYP2C9—brain cancer	1.2e-05	0.000135	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IRS2—brain cancer	1.2e-05	0.000135	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—BSG—brain cancer	1.19e-05	0.000134	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—DLL1—brain cancer	1.19e-05	0.000133	CbGpPWpGaD
Erlotinib—MKNK1—Disease—STAT3—brain cancer	1.19e-05	0.000133	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—HES1—brain cancer	1.17e-05	0.000131	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—brain cancer	1.17e-05	0.000131	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—VEGFA—brain cancer	1.17e-05	0.000131	CbGpPWpGaD
Erlotinib—JAK3—Immune System—IL2—brain cancer	1.15e-05	0.00013	CbGpPWpGaD
Erlotinib—EGFR—Immune System—VAV1—brain cancer	1.13e-05	0.000127	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ENO2—brain cancer	1.13e-05	0.000127	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—IL2—brain cancer	1.12e-05	0.000126	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—RELA—brain cancer	1.12e-05	0.000126	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—BSG—brain cancer	1.12e-05	0.000126	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—ERBB2—brain cancer	1.12e-05	0.000126	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PDGFRA—brain cancer	1.11e-05	0.000125	CbGpPWpGaD
Erlotinib—JAK3—Immune System—CTNNB1—brain cancer	1.11e-05	0.000125	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—CTNNB1—brain cancer	1.11e-05	0.000124	CbGpPWpGaD
Erlotinib—MKNK1—Disease—MYC—brain cancer	1.1e-05	0.000124	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—RELA—brain cancer	1.1e-05	0.000123	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—ERBB2—brain cancer	1.09e-05	0.000123	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—RELA—brain cancer	1.09e-05	0.000122	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—ERBB2—brain cancer	1.08e-05	0.000122	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PDGFRA—brain cancer	1.08e-05	0.000122	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—SPP1—brain cancer	1.08e-05	0.000121	CbGpPWpGaD
Erlotinib—MKNK1—Disease—EGFR—brain cancer	1.08e-05	0.000121	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—IL2—brain cancer	1.07e-05	0.000121	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—APC—brain cancer	1.06e-05	0.000119	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—PIK3CG—brain cancer	1.06e-05	0.000119	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYP2C9—brain cancer	1.05e-05	0.000119	CbGpPWpGaD
Erlotinib—NR1I2—Gene Expression—MYC—brain cancer	1.05e-05	0.000118	CbGpPWpGaD
Erlotinib—EGFR—Disease—VAV1—brain cancer	1.04e-05	0.000117	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—brain cancer	1.03e-05	0.000116	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—BSG—brain cancer	1.03e-05	0.000116	CbGpPWpGaD
Erlotinib—ALB—Metabolism—BSG—brain cancer	1.02e-05	0.000115	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—IDH1—brain cancer	1.02e-05	0.000115	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—brain cancer	1.02e-05	0.000115	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SHH—brain cancer	1.01e-05	0.000114	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYP2C9—brain cancer	9.93e-06	0.000112	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—IL2—brain cancer	9.87e-06	0.000111	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—CTNNB1—brain cancer	9.77e-06	0.00011	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IRS2—brain cancer	9.76e-06	0.00011	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—VEGFA—brain cancer	9.74e-06	0.00011	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TRPC6—brain cancer	9.73e-06	0.000109	CbGpPWpGaD
Erlotinib—JAK3—Immune System—STAT3—brain cancer	9.69e-06	0.000109	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—IDH1—brain cancer	9.64e-06	0.000109	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—STAT3—brain cancer	9.64e-06	0.000108	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—EGFR—brain cancer	9.64e-06	0.000108	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CCND1—brain cancer	9.62e-06	0.000108	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—RELA—brain cancer	9.6e-06	0.000108	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SMO—brain cancer	9.56e-06	0.000108	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PTCH1—brain cancer	9.56e-06	0.000108	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—VEGFA—brain cancer	9.55e-06	0.000107	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—ERBB2—brain cancer	9.54e-06	0.000107	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CTNNB1—brain cancer	9.53e-06	0.000107	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IRS2—brain cancer	9.48e-06	0.000107	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—CTNNB1—brain cancer	9.45e-06	0.000106	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PDGFRA—brain cancer	9.23e-06	0.000104	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—RELA—brain cancer	9.22e-06	0.000104	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—ERBB2—brain cancer	9.16e-06	0.000103	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—VEGFA—brain cancer	9.12e-06	0.000103	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	8.98e-06	0.000101	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—BSG—brain cancer	8.96e-06	0.000101	CbGpPWpGaD
Erlotinib—EGFR—Disease—HES1—brain cancer	8.95e-06	0.000101	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—IDH1—brain cancer	8.84e-06	9.95e-05	CbGpPWpGaD
Erlotinib—JAK3—Immune System—EGFR—brain cancer	8.8e-06	9.91e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—IDH1—brain cancer	8.79e-06	9.89e-05	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—EGFR—brain cancer	8.76e-06	9.86e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PIK3CG—brain cancer	8.62e-06	9.7e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—APC—brain cancer	8.62e-06	9.7e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PDGFRA—brain cancer	8.52e-06	9.59e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—BSG—brain cancer	8.44e-06	9.5e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP2C9—brain cancer	8.41e-06	9.46e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—VEGFA—brain cancer	8.39e-06	9.44e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—CTNNB1—brain cancer	8.35e-06	9.39e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—VEGFA—brain cancer	8.32e-06	9.36e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—STAT3—brain cancer	8.31e-06	9.35e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—RELA—brain cancer	8.26e-06	9.3e-05	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	8.26e-06	9.3e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—STAT3—brain cancer	8.24e-06	9.27e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—ERBB2—brain cancer	8.21e-06	9.24e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IRS2—brain cancer	8.1e-06	9.12e-05	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	8.08e-06	9.1e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ENO2—brain cancer	8.07e-06	9.08e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—PIK3CG—brain cancer	7.86e-06	8.85e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	7.85e-06	8.84e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—PIK3CG—brain cancer	7.83e-06	8.81e-05	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—EGFR—brain cancer	7.74e-06	8.71e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—MYC—brain cancer	7.72e-06	8.69e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—IDH1—brain cancer	7.7e-06	8.67e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NOTCH2—brain cancer	7.64e-06	8.6e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ENO2—brain cancer	7.62e-06	8.58e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—EGFR—brain cancer	7.55e-06	8.5e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—IRS2—brain cancer	7.48e-06	8.42e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IL2—brain cancer	7.44e-06	8.38e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VAV1—brain cancer	7.29e-06	8.2e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—IDH1—brain cancer	7.26e-06	8.17e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CCND1—brain cancer	7.26e-06	8.17e-05	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—TP53—brain cancer	7.22e-06	8.12e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	7.2e-06	8.1e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CTNNB1—brain cancer	7.19e-06	8.09e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	7.16e-06	8.06e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—BSG—brain cancer	7.15e-06	8.05e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ENO2—brain cancer	6.99e-06	7.86e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ENO2—brain cancer	6.95e-06	7.82e-05	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	6.79e-06	7.64e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—RELA—brain cancer	6.74e-06	7.58e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—ERBB2—brain cancer	6.69e-06	7.53e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—APC—brain cancer	6.61e-06	7.44e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—RELA—brain cancer	6.54e-06	7.36e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—ERBB2—brain cancer	6.5e-06	7.32e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP2C9—brain cancer	6.49e-06	7.3e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TP53—brain cancer	6.34e-06	7.13e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—VEGFA—brain cancer	6.33e-06	7.12e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HES1—brain cancer	6.27e-06	7.05e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—STAT3—brain cancer	6.26e-06	7.05e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—IDH1—brain cancer	6.15e-06	6.92e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PIK3CG—brain cancer	6.09e-06	6.85e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ENO2—brain cancer	6.09e-06	6.85e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL2—brain cancer	6.07e-06	6.83e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PDGFRA—brain cancer	5.97e-06	6.72e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CCND1—brain cancer	5.91e-06	6.66e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL2—brain cancer	5.89e-06	6.63e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CTNNB1—brain cancer	5.86e-06	6.59e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MYC—brain cancer	5.82e-06	6.55e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SPP1—brain cancer	5.79e-06	6.52e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ENO2—brain cancer	5.74e-06	6.46e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—EGFR—brain cancer	5.69e-06	6.41e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CTNNB1—brain cancer	5.69e-06	6.4e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PIK3CG—brain cancer	5.68e-06	6.39e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—RELA—brain cancer	5.59e-06	6.29e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—ERBB2—brain cancer	5.56e-06	6.25e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—IL2—brain cancer	5.53e-06	6.23e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—BSG—brain cancer	5.52e-06	6.21e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL2—brain cancer	5.51e-06	6.2e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IRS2—brain cancer	5.24e-06	5.9e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CG—brain cancer	5.17e-06	5.81e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—VEGFA—brain cancer	5.16e-06	5.8e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—ERBB2—brain cancer	5.13e-06	5.77e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—STAT3—brain cancer	5.11e-06	5.75e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL2—brain cancer	5.04e-06	5.67e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	5.01e-06	5.63e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—STAT3—brain cancer	4.96e-06	5.58e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CTNNB1—brain cancer	4.86e-06	5.47e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ENO2—brain cancer	4.86e-06	5.47e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TP53—brain cancer	4.78e-06	5.38e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—IDH1—brain cancer	4.75e-06	5.34e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MYC—brain cancer	4.74e-06	5.34e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—VEGFA—brain cancer	4.7e-06	5.29e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—EGFR—brain cancer	4.64e-06	5.22e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—APC—brain cancer	4.63e-06	5.21e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CG—brain cancer	4.63e-06	5.21e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—EGFR—brain cancer	4.51e-06	5.07e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CTNNB1—brain cancer	4.49e-06	5.05e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—STAT3—brain cancer	4.24e-06	4.77e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—STAT3—brain cancer	3.91e-06	4.4e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—brain cancer	3.9e-06	4.38e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ENO2—brain cancer	3.75e-06	4.22e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CG—brain cancer	3.7e-06	4.17e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MYC—brain cancer	3.64e-06	4.09e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—RELA—brain cancer	3.62e-06	4.07e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ERBB2—brain cancer	3.59e-06	4.04e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—brain cancer	3.55e-06	4e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CG—brain cancer	3.5e-06	3.94e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL2—brain cancer	3.26e-06	3.66e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CG—brain cancer	3.21e-06	3.61e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CG—brain cancer	3.19e-06	3.59e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCND1—brain cancer	3.17e-06	3.57e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CTNNB1—brain cancer	3.14e-06	3.54e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CG—brain cancer	2.79e-06	3.14e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VEGFA—brain cancer	2.77e-06	3.11e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—STAT3—brain cancer	2.74e-06	3.08e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CG—brain cancer	2.63e-06	2.96e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MYC—brain cancer	2.55e-06	2.87e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CG—brain cancer	2.23e-06	2.51e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—brain cancer	2.09e-06	2.35e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CG—brain cancer	1.72e-06	1.94e-05	CbGpPWpGaD
